Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310754337> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4310754337 endingPage "S1469" @default.
- W4310754337 startingPage "S1469" @default.
- W4310754337 abstract "Unresectable biliary tract cancer (BTC) has a poor prognosis despite treated with the standard combination chemotherapy. We aimed to evaluate the efficacy, safety, and biomarkers of radiotherapy and camrelizumab as first-line therapy in unresectable BTC. In this single-arm, phase II study, patients with histopathologically confirmed unresectable BTC without distant metastases received external radiotherapy with a dose of ≥45 Gy (2-2.5 Gy per fraction), followed by anti-PD-1 immunotherapy (camrelizumab 200mg once, every 3 weeks) initiated within 7 days after completion of radiotherapy as first-line therapy. Treatment was continued until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS). The secondary endpoints included safety, objective response rate (ORR), disease control rate (DCR), and overall survival (OS). Integrated biomarker analyses were also performed. Between December, 2019 and March, 2021, a total of 36 patients with unresectable BTC were enrolled after assessing 50 patients for eligibility. All eligible patients [23 (63.9%) male; median (range) age, 62 (28-75) years] completed radiotherapy and at least one cycle of camrelizumab. With a median follow-up of 19 months (IQR 12-24), the median PFS and OS were 12 months (95% CI, 8-not estimable) and 22 months (95% CI, 15-not estimable), respectively. And the 1-year PFS rate was 44%. The ORR was 61.1% [95% CI, 43.5-76.9], and the DCR was 86.1% [95% CI, 70.5-95.3]. In addition, median OS was prolonged in patients with high of tumor mutational burden (TMB) compared with those with low TMB (24 vs. 15 months, nominal p=0.041). Five (13.9%) patients experienced grade ≥3 treatment-related adverse effects, including decreased lymphocyte (5.6%), bullous dermatitis (2.8%), decreased platelet count (2.8%), and deep-vein thrombosis (2.8%). External radiotherapy followed by camrelizumab indicated an acceptable antitumor activity and low toxicity levels in unresectable BTC without distant metastases as the first-line therapy, the efficacy of this regimen was related to the TMB status, but warranting further investigation." @default.
- W4310754337 created "2022-12-17" @default.
- W4310754337 creator A5011616722 @default.
- W4310754337 creator A5013852881 @default.
- W4310754337 creator A5015346622 @default.
- W4310754337 creator A5019319993 @default.
- W4310754337 creator A5024856509 @default.
- W4310754337 creator A5030730190 @default.
- W4310754337 creator A5035163484 @default.
- W4310754337 creator A5047375095 @default.
- W4310754337 creator A5050593912 @default.
- W4310754337 creator A5079753471 @default.
- W4310754337 creator A5086721500 @default.
- W4310754337 creator A5090717987 @default.
- W4310754337 date "2022-11-01" @default.
- W4310754337 modified "2023-10-18" @default.
- W4310754337 title "89P Radiotherapy followed by camrelizumab for unresectable biliary tract cancer: A phase II clinical trial" @default.
- W4310754337 doi "https://doi.org/10.1016/j.annonc.2022.10.125" @default.
- W4310754337 hasPublicationYear "2022" @default.
- W4310754337 type Work @default.
- W4310754337 citedByCount "0" @default.
- W4310754337 crossrefType "journal-article" @default.
- W4310754337 hasAuthorship W4310754337A5011616722 @default.
- W4310754337 hasAuthorship W4310754337A5013852881 @default.
- W4310754337 hasAuthorship W4310754337A5015346622 @default.
- W4310754337 hasAuthorship W4310754337A5019319993 @default.
- W4310754337 hasAuthorship W4310754337A5024856509 @default.
- W4310754337 hasAuthorship W4310754337A5030730190 @default.
- W4310754337 hasAuthorship W4310754337A5035163484 @default.
- W4310754337 hasAuthorship W4310754337A5047375095 @default.
- W4310754337 hasAuthorship W4310754337A5050593912 @default.
- W4310754337 hasAuthorship W4310754337A5079753471 @default.
- W4310754337 hasAuthorship W4310754337A5086721500 @default.
- W4310754337 hasAuthorship W4310754337A5090717987 @default.
- W4310754337 hasBestOaLocation W43107543371 @default.
- W4310754337 hasConcept C126322002 @default.
- W4310754337 hasConcept C141071460 @default.
- W4310754337 hasConcept C143998085 @default.
- W4310754337 hasConcept C203092338 @default.
- W4310754337 hasConcept C2776694085 @default.
- W4310754337 hasConcept C2778424827 @default.
- W4310754337 hasConcept C2779984678 @default.
- W4310754337 hasConcept C2780739268 @default.
- W4310754337 hasConcept C31760486 @default.
- W4310754337 hasConcept C509974204 @default.
- W4310754337 hasConcept C535046627 @default.
- W4310754337 hasConcept C71924100 @default.
- W4310754337 hasConcept C90924648 @default.
- W4310754337 hasConceptScore W4310754337C126322002 @default.
- W4310754337 hasConceptScore W4310754337C141071460 @default.
- W4310754337 hasConceptScore W4310754337C143998085 @default.
- W4310754337 hasConceptScore W4310754337C203092338 @default.
- W4310754337 hasConceptScore W4310754337C2776694085 @default.
- W4310754337 hasConceptScore W4310754337C2778424827 @default.
- W4310754337 hasConceptScore W4310754337C2779984678 @default.
- W4310754337 hasConceptScore W4310754337C2780739268 @default.
- W4310754337 hasConceptScore W4310754337C31760486 @default.
- W4310754337 hasConceptScore W4310754337C509974204 @default.
- W4310754337 hasConceptScore W4310754337C535046627 @default.
- W4310754337 hasConceptScore W4310754337C71924100 @default.
- W4310754337 hasConceptScore W4310754337C90924648 @default.
- W4310754337 hasLocation W43107543371 @default.
- W4310754337 hasOpenAccess W4310754337 @default.
- W4310754337 hasPrimaryLocation W43107543371 @default.
- W4310754337 hasRelatedWork W1608269846 @default.
- W4310754337 hasRelatedWork W2133349049 @default.
- W4310754337 hasRelatedWork W2160139566 @default.
- W4310754337 hasRelatedWork W2404042595 @default.
- W4310754337 hasRelatedWork W2789668336 @default.
- W4310754337 hasRelatedWork W3021135223 @default.
- W4310754337 hasRelatedWork W3210456462 @default.
- W4310754337 hasRelatedWork W4282918911 @default.
- W4310754337 hasRelatedWork W4304690509 @default.
- W4310754337 hasRelatedWork W4313545978 @default.
- W4310754337 hasVolume "33" @default.
- W4310754337 isParatext "false" @default.
- W4310754337 isRetracted "false" @default.
- W4310754337 workType "article" @default.